Urinary tract infections (UTIs) are among the most common causes of hospitalization in children, with a rising prevalence of extended-spectrum beta-lactamase-producing organisms (ESBL). The purpose of this study was to identify risk factors and treatment outcomes of children with ESBL-UTI. A retrospective case-control study of hospitalized children was performed from July 2014 till December 2017. Medical records from patients with a positive urine culture were reviewed and included in the study if they met criteria for UTI. Cases were defined as ESBL-UTI, while controls were defined as non-ESBL-UTI patients. This study confirmed that there are certain risk factors, such as previous UTI, recent antibiotic use, urinary tract abnormalities, recent hospital admission, and nonrenal comorbidities, that are associated with ESBL-UTI. Most of the patients with ESBL-UTI responded to discordant antibiotics. Other significant outcomes in patients with ESBL-UTI included a longer length of stay and longer intravenous antibiotic therapy.
SpencerJDSchwadererAMcHughKHainsDS. Pediatric urinary tract infections: an analysis of hospitalizations, charges, and costs in the USA. Pediatr Nephrol. 2010;25(12):2469-2475.
3.
World Health Organization. Antimicrobial Resistance Global Report on Surveillance: 2014 Summary. World Health Organization; 2014.
4.
Flores-MirelesALWalkerJNCaparonMHultgrenSJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269-284.
5.
ZaoutisTEGoyalMChuJH, et al. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children. Pediatrics. 2005;115(4):942-949.
6.
FlokasMEDetsisMAlevizakosMMylonakisE. Prevalence of ESBL-producing enterobacteriaceae in paediatric urinary tract infections: a systematic review and meta-analysis. J Infect. 2016;73(6):547-557.
7.
LoganLKBraykovNPWeinsteinRALaxminarayanR; CDC Epicenters Prevention Program. Extended-spectrum β-lactamase–producing and third-generation cephalosporin-resistant enterobacteriaceae in children: trends in the United States, 1999–2011. J Pediatr Infect Dis Soc. 2014;3(4):320-328.
8.
LobSHNicolleLEHobanDJKazmierczakKMBadalRESahmDF. Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010–2014. Diagn Microbiol Infect Dis. 2016;85(4):459-465.
9.
StryskoJPMonyVClevelandJSiddiquiHHomelPGagliardoC. International travel is a risk factor for extended-spectrum β-lactamase-producing Enterobacteriaceae acquisition in children: a case-case-control study in an urban US hospital. Travel Med Infect Dis. 2016;14(6):568-571.
10.
DayanNDabbahHWeissmanIAgaIEvenLGlikmanD. Urinary tract infections caused by community-acquired extended-spectrum β-lactamase-producing and nonproducing bacteria: a comparative study. J Pediatr. 2013;163(5):1417-1421.
11.
Subcommittee on Urinary Tract Infection. Reaffirmation of AAP clinical practice guideline: the diagnosis and management of the initial urinary tract infection in febrile infants and young children 2-24 months of age. Pediatrics. 2016;138(6):e20163026. doi:10.1542/peds.2016-3026.
12.
LebowitzRLOlbingHParkkulainenKVSmellieJMTamminen-MöbiusTE. International system of radiographic grading of vesicoureteric reflux. Pediatr Radiol. 1985;15(2):105-109.
13.
BlaschkeAJKorgenskiEKDalyJALaFleurBPaviaATByingtonCL. Extended-spectrum β-lactamase-producing pathogens in a children’s hospital: a 5-year experience. Am J Infect Control. 2009;37(6):435-441.
14.
DegnanLAMilstoneAMDiener-WestMLeeCK. Extended-spectrum beta-lactamase bacteria from urine isolates in children. J Pediatr Pharmacol Ther. 2015;20(5):373-377.
Uyar AksuNEkinciZDundarDBaydemirC. Childhood urinary tract infection caused by extended-spectrumbeta-lactamase-producing bacteria: risk factors and empiric therapy. Pediatr Int. 2017;59(2):176-180.
17.
ZhuFHRodadoMPAsmarBISalimniaHThomasRAbdel-HaqN. Risk factors for community acquired urinary tract infections caused by extended spectrum β-lactamase (ESBL) producing Escherichia coli in children: a case control study. Infect Dis (Lond). 2019;51(11-12):802-809. doi:10.1080/23744235.2019.1654127.
18.
KizilcaOSiraneciRYilmazA, et al. Risk factors for community-acquired urinary tract infection caused by ESBL-producing bacteria in children. Pediatr Int. 2012;54(6):858-862.
19.
WangMELeeVGreenhowTL, et al. Clinical response to discordant therapy in third-generation cephalosporin-resistant UTIs. Pediatrics. 2020;145(2):e20191608. doi:10.1542/peds.2019-1608.
20.
MadhiFJungCTimsitS, et al. Febrile urinary-tract infection due to extended-spectrum beta-lactamase–producing enterobacteriaceae in children: a French prospective multicenter study. PLoS One. 2018;13(1):e0190910.
21.
TratselasASimitsopoulouMGiannakopoulouA, et al. Effect of ceftriaxone on the outcome of murine pyelonephritis caused by extended-spectrum-beta-lactamase-producing Escherichia coli. Antimicrob Agents Chemother. 2014;58(12):7102-7111.
22.
Peco-AntićAParipovićDBuljugićS, et al. In vivo susceptibility of ESBL producing Escherichia coli to ceftriaxone in children with acute pyelonephritis. Srp Arh Celok Lek. 2012;140(5-6):321-325.
23.
NieminenOKorppiMHelminenM. Healthcare costs doubled when children had urinary tract infections caused by extended-spectrum β-lactamase-producing bacteria. Acta Paediatr. 2017;106(2):327-333.
24.
BeyturAYakupogullariYOguzFOtluBKaysaduH. Oral amoxicillin-clavulanic acid treatment in urinary tract infections caused by extended-spectrum beta-lactamase-producing organisms. Jundishapur J Microbiol. 2014;8(1):e13792.
25.
MahonyMMcMullanBBrownJKennedySE. Multidrug-resistant organisms in urinary tract infections in children. Pediatr Nephrol. 2020;35(9):1563-1573.
